|1.||Butenas, Saulius: 5 articles (04/2012 - 01/2008)|
|2.||Undas, Anetta: 5 articles (04/2012 - 01/2008)|
|3.||Gailani, David: 4 articles (09/2014 - 08/2006)|
|4.||Tuma, Ronald F: 2 articles (02/2013 - 07/2012)|
|5.||Navaneetham, Duraiswamy: 2 articles (02/2013 - 07/2012)|
|6.||Wu, Wenman: 2 articles (02/2013 - 07/2012)|
|7.||Walsh, Peter N: 2 articles (02/2013 - 07/2012)|
|8.||Li, Hongbo: 2 articles (02/2013 - 07/2012)|
|9.||Travers, Richard J: 1 article (09/2015)|
|10.||Diamond, Scott L: 1 article (09/2015)|
09/10/2007 - "These results demonstrate that pharmacologic inhibition of factor XIa achieves antithrombotic efficacy with minimal effects on provoked bleeding."
01/01/2015 - "Activated factor XI (FXIa) inhibitors are anticipated to combine anticoagulant and profibrinolytic effects with a low bleeding risk. "
02/13/2014 - "Antithrombotic agents that are inhibitors of factor XIa (FXIa) have the potential to demonstrate robust efficacy with a low bleeding risk profile. "
02/14/2013 - "Inhibition of factor XIa (FXIa) is a novel paradigm for developing anticoagulants without major bleeding consequences. "
10/01/2008 - "Activation of factor IX by factor XIa is required in certain situations to prevent bleeding from premature clot degradation. "
|2.||Hemophilia B (Haemophilia B)
05/01/2000 - "In a previous study, we prepared a monoclonal antibody (MoAb) to coagulation factor IX (FIX), designated 65-10, which interfered with the activation of FIX by the activated factor XI/Ca(2+) and neutralized the prolonged ox brain prothrombin time of hemophilia B(M) [11,12]. "
12/01/1981 - "Factor IXChapel Hill (Factor IXCH), an abnormal Factor IX molecule isolated from the plasma of a patient with mild hemophilia B, has previously been shown to exhibit delayed activation by Factor XIa and calcium. "
07/01/1999 - "Factor IXR94S is a naturally occurring hemophilia B defect, which results from an Arg 94 to Ser mutation in the second epidermal growth factor (EGF)-like module of factor IX. Recombinant factor IXR94S was activated by factor XIa/calcium with an approximately 50-fold reduced rate and by factor VIIa/tissue factor/phospholipid/calcium with an approximately 20-fold reduced rate compared with wild-type factor IX. The apparent molecular mass of the light chain of factor IXaR94S was approximately 6 kD higher than that of plasma or wild-type factor IX, which was not corrected by N-glycosidase F digestion. "
09/17/2015 - "In this issue of Blood, Zhu et al have established, in human blood, that factor XIa and polyphosphate make significant contributions to thrombus formation. "
09/01/2014 - "Coagulation factor XIa has emerged as a novel target for safer anticoagulant therapy because of its role in thrombosis and its relatively small contribution to hemostasis. "
09/01/1970 - "Purified contact activation product of the coagulation system in experimental thrombosis."
12/12/2013 - "Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo."
02/01/2013 - "The kunitz protease inhibitor domain of PN2 (PN2KPI) is a potent and specific inhibitor (K(i) 0.5-2 nM) of factor XIa (FXIa) and inhibits cerebrovascular thrombosis in mice. "
|4.||Acute Coronary Syndrome
04/01/2012 - "Circulating active tissue factor (TF) and activated factor XI (FXIa) have been detected in subgroups of acute coronary syndromes (ACSs) and stable angina patients. "
03/01/2011 - "Previously, circulating active tissue factor (TF) and factor XIa (FXIa) have been reported to be associated with acute coronary syndromes. "
09/01/2010 - "Circulating activated factor XI (FXIa) and active tissue factor (TF) can be detected in acute coronary syndromes and stable angina. "
12/01/1972 - "The inhibitory properties of plasma against activated plasma thromboplastin antecedent (factor XIa) in hereditary angioneurotic edema."
05/05/1983 - "Patients with hereditary angioedema lack C-1 inhibitor, a plasma alpha 2-glycoprotein that inhibits both the proteolytic action of C1, the activated first component of the complement system, and the activity of components of the contact phase of coagulation: kallikrein, factor XIa, and factor XIIa. "
|1.||Fibrinolytic Agents (Antithrombotic Agents)
|2.||Factor IX (PTC)
|3.||Thromboplastin (Tissue Factor)
|5.||Factor XIIa (Coagulation Factor XIIa)
|6.||Protease Inhibitors (Protease Inhibitor)
|7.||Factor XI (Plasma Thromboplastin Antecedent)
|8.||Factor VIII (Coagulation Factor VIII)
|10.||alpha 1-Antitrypsin (alpha 1 Antitrypsin)